The third largest Therapy Area (TA) of the Indian Pharmaceutical Market (IPM) is Gastroenterology. It garners approximately 11% of the total Indian Pharmaceutical Market (IPM) value. With increasing innovations in this TA, the segment is set to grow significantly in the near future.
Alkem understands the importance of evolution in gastrointestinal medicines to counter the ever-evolving disorders of GI tract. Alkem commands around 6% of the total revenue generated by this TA.
Presently, Alkem is the 3rd largest company in GI Therapy Area (TA) of the Indian Pharmaceutical Market (IPM). Over the years, we have developed several products for GI disorders like GERD, gastric ulcers, constipation, hyperacidity, diarrhoea, worm infestation etc.
Some of the highlights of Alkem’s Gastroenterology portfolio are
* MAT May 2019